Healing & Recovery Peptides

BPC-157 is the most popular healing peptide in the world, backed by 180+ PubMed papers and consistent user reports from tens of thousands of people. Community evidence for tendon and gut repair is hard to dismiss, though formal human trials remain limited to about 30 subjects total.

TB-500 is the most popular systemic healing peptide in the research community, with 500+ forum threads and a 4.1/5 sentiment score. Backed by strong preclinical wound-healing data but zero completed human trials for the fragment itself. Inject anywhere; it reaches the injury regardless of site.

The Wolverine Stack (BPC-157 + TB-500) combines two healing peptides in one pre-mixed vial. One published human combination report showed 14/16 patients with significant pain relief. Tens of thousands of community reports back up the science. No dedicated clinical trial exists yet, but this remains the most popular healing stack available.

Thymosin beta-4 is the full-length 43-amino-acid healing protein behind the Ac-SDKP cardioprotective domain that TB-500 lacks. Phase II wound data showed 67% complete healing vs 25% placebo. Community experience across hundreds of users backs consistent soft tissue recovery within 2 to 4 weeks.

Linaclotide (Linzess) is one of the few peptides you swallow rather than inject. FDA-approved for IBS-C and chronic constipation, it works locally inside the gut to increase fluid secretion and reduce visceral pain. Diarrhea at higher doses is the trade-off; community users often find lower doses equally effective.

The GLOW Blend adds GHK-Cu to the Wolverine Stack for three-pathway healing: local tissue repair, systemic inflammation control, and collagen remodeling. Community reports are strong; human clinical data is nonexistent for the combination. Users typically run 4-week on, 2-week off cycles.

KLOW Blend packs BPC-157, TB-500, GHK-Cu, and KPV into one 80mg recovery vial. Community users report improved skin elasticity and gut comfort during GLP-1 therapy. No human trials exist for the combined formulation, but individual component data spans hundreds of preclinical studies.

Teduglutide (Gattex/Revestive) is the only FDA-approved GLP-2 analog for short bowel syndrome. The STEPS trial showed 63% of patients reduced parenteral nutrition needs at 24 weeks. Cost sits near $520K per year, and intestinal adaptation reverses if you stop treatment.

B7-33 is a biased RXFP1 agonist that halved infarct size in mouse cardiac models without the tumor-promoting cAMP signaling of native relaxin-2. All data is preclinical. The 6-minute serum half-life and zero human trials make this a research-only compound with promising but unconfirmed anti-fibrotic potential.

CGRP is the body's most potent vasodilator and the central target behind all modern migraine biologics. Strong preclinical evidence supports cardioprotective and wound healing roles. Exogenous use is IV-only with a 6.9-minute half-life, restricting it to controlled research settings.

Endomorphin-1 and Endomorphin-2 are the body's own mu-opioid receptor agonists, binding with selectivity no other endogenous peptide matches. Still research-only, with a plasma half-life measured in minutes. CYT-1010, a stabilized analog, showed analgesia without respiratory depression in Phase I trials.

Dermorphin is a frog-derived opioid peptide with 30-40x morphine's analgesic potency. One 1985 human RCT showed superiority over morphine for postoperative pain; no further clinical trials exist. Likely classified as a Schedule I analog under US federal law. Research reference only, not for human use.

Ziconotide (Prialt) is an FDA-approved cone snail venom peptide for severe refractory pain. Delivered by intrathecal pump, it blocks Cav2.2 calcium channels without opioid tolerance or respiratory depression. Black Box Warning for psychiatric and cognitive side effects including confusion and hallucinations.

Carbetocin is a long-acting oxytocin analog given as a single 100 mcg injection after delivery to prevent postpartum hemorrhage. Approved in 40+ countries and backed by the 29,645-patient CHAMPION trial, it's on the WHO Essential Medicines List. Not FDA-approved in the US.

Calcitonin (Miacalcin) is an FDA-approved 32-amino-acid peptide that inhibits bone resorption. Positioned as last-line for osteoporosis, its real strength is acute bone pain relief and rapid serum calcium reduction in emergencies. Available in nasal spray and subcutaneous injection formulations.

Bronchogen (AEDL) is a Khavinson tetrapeptide bioregulator targeting bronchial and pulmonary tissue through gene expression modulation. Rat COPD studies showed epithelial remodeling reversal after 30-day oral courses. No human trials exist. Oral capsule format at 10 to 20 mg daily, cycled every 4 to 6 months per standard bioregulator protocol.

Nesiritide (Natrecor) is a recombinant BNP that lowers pulmonary pressures within 15 minutes in acute heart failure. FDA-approved in 2001 but discontinued after ASCEND-HF (n=7,141) showed no mortality benefit. Hospital-only IV drug with no approved community use or self-administration potential.

Plecanatide (Trulance) is an FDA-approved oral GC-C agonist for CIC and IBS-C. Same class as linaclotide but with far lower diarrhea rates (5% vs 19%). One fixed 3 mg tablet daily; no titration required. Approved for adults 18 and older.

Apelin-12 produced the strongest blood pressure reduction of any apelin isoform in rat studies, dropping MAP by 26 mmHg at a single IV dose. Plasma half-life sits around five minutes. Zero human clinical trials exist for native apelin-12. Strictly a preclinical research compound.

Larazotide acetate is an oral peptide that blocks zonulin-mediated tight junction opening in the gut. Phase 2b showed 26% fewer symptomatic days in celiac patients, though Phase 3 failed at interim analysis. No injection required. Safety matched placebo closely.

ARA-290 (cibinetide) activates the innate repair receptor to drive small nerve fiber regeneration without affecting red blood cell production. Phase 2b trials in sarcoidosis neuropathy showed a 23% increase in corneal nerve fiber area at the 4 mg dose. Research-only; no Phase 3 registered.

Cardiogen (AEDR) is a Khavinson tetrapeptide bioregulator targeting cardiac tissue gene expression. Picomolar concentrations stimulated cardiomyocyte proliferation in rat tissue cultures; no human trials exist. Used within multi-organ bioregulator longevity stacks, not as a standalone peptide. Research-only with preclinical evidence from a single lab group.

Cartalax is a tripeptide bioregulator (AED) targeting cartilage tissue at the gene expression level. Preclinical data shows chondrocyte proliferation and MMP-9 inhibition in rat models. No human trials exist. The small community using it reports subtle joint stiffness improvements over 30-day oral courses.